Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Interest Expenses (2018 - 2025)

X4 Pharmaceuticals' Interest Expenses history spans 8 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 5.12% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $8.9 million, up 1.23%, while the annual FY2025 figure was $8.9 million, 1.23% up from the prior year.
  • Interest Expenses reached $2.2 million in Q4 2025 per XFOR's latest filing, down from $2.3 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $2.4 million in Q3 2024 to a low of $891000.0 in Q1 2021.
  • Average Interest Expenses over 5 years is $1.6 million, with a median of $1.4 million recorded in 2023.
  • Peak YoY movement for Interest Expenses: soared 89.55% in 2024, then decreased 6.5% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $925000.0 in 2021, then increased by 23.68% to $1.1 million in 2022, then skyrocketed by 64.86% to $1.9 million in 2023, then rose by 22.16% to $2.3 million in 2024, then fell by 5.12% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Interest Expenses are $2.2 million (Q4 2025), $2.3 million (Q3 2025), and $2.2 million (Q2 2025).